These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27392398)

  • 1. Synthesis of Optically Active 1,4-Thiazane-3-carboxylic Acid via Optical Resolution by Preferential Crystallization of (RS)-2-Amino-3-[(2-chloroethyl)sulfanyl]propanoic Acid Hydrochloride.
    Shiraiwa T; Tadokoro K; Tanaka H; Nanba K; Yokono N; Shibazaki K; Kubo M; Kurokawa H
    Biosci Biotechnol Biochem; 1998; 62(12):2382-7. PubMed ID: 27392398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical Resolution by Preferential Crystallization of (RS)-2-Amino-3-(2-carboxyethylthio)propanoic Acid.
    Shiraiwa T; Kubo M; Watanabe M; Nakatani H; Ohkubo M; Kurokawa H
    Biosci Biotechnol Biochem; 1998; 62(4):818-20. PubMed ID: 27392566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of four stereoisomers of 1,4-thiazane-3-carboxylic acid 1-oxide via the asymmetric transformation (combined isomerization-preferential crystallization) of 1,4-thiazane-3-carboxylic acid.
    Shiraiwa T; Tadokoro K; Ishikawa J; Tanaka H; Masaki T; Kurokawa H
    Biosci Biotechnol Biochem; 2000 Feb; 64(2):341-7. PubMed ID: 10737191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical resolution by preferential crystallization of (RS)-2-benzoylamino-2-benzyl-3-hydroxypropanoic acid and its use in synthesizing optically active 2-amino-2-methyl-3-phenylpropanoic acid.
    Shiraiwa T; Suzuki M; Sakai Y; Nagasawa H; Takatani K; Noshi D; Yamanashi K
    Chem Pharm Bull (Tokyo); 2002 Oct; 50(10):1362-6. PubMed ID: 12372863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of optically active (2RS,3SR)-2-amino-3-hydroxy-3-phenylpropanoic acid (threo-beta-phenylserine) via optical resolutions by replacing and preferential crystallization.
    Shiraiwa T; Kawashima Y; Ikaritani A; Suganuma Y; Saijoh R
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1170-4. PubMed ID: 16880663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of optically active 2-aminobutanoic acid via optical resolution by replacing crystallization.
    Yajima T; Aizawa Y; Nishida M; Sakaguchi Y; Shiraiwa T
    Biosci Biotechnol Biochem; 2007 May; 71(5):1338-41. PubMed ID: 17485843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of optically active threo-2-amino-3-hydroxy-3-phenylpropanoic acid (threo-beta-phenylserine) via optical resolution.
    Shiraiwa T; Saijoh R; Suzuki M; Yoshida K; Nishimura S; Nagasawa H
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1363-7. PubMed ID: 14646310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical Resolution by the Replacing Crystallization of DL-Threonine with L-Alanine as an Optically Active Cosolute.
    Shiraiwa T; Kubo M; Fukuda K; Kurokawa H
    Biosci Biotechnol Biochem; 1999; 63(12):2212-5. PubMed ID: 27373922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of optically active allothreonine via optical resolution by replacing crystallization.
    Shiraiwa T; Fukuda K; Kubo M
    Chem Pharm Bull (Tokyo); 2002 Feb; 50(2):287-91. PubMed ID: 11848226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical resolution by preferential crystallization of (1RS,3RS)-1,2,3,4-tetrahydro-6,7-dihydroxy-1-methyl-3-isoquinolinecarboxylic acid.
    Shiraiwa T; Kiyoe R
    Chem Pharm Bull (Tokyo); 2005 Sep; 53(9):1197-9. PubMed ID: 16141597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of optically active homocysteine from methionine and its use in preparing four stereoisomers of cystathionine.
    Shiraiwa T; Nakagawa K; Kanemoto N; Kinda T; Yamamoto H
    Chem Pharm Bull (Tokyo); 2002 Aug; 50(8):1081-5. PubMed ID: 12192140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical resolution of a 1,5-benzothiazepine derivative, a synthetic intermediate of diltiazem, by preferential crystallization and diastereomeric salt formation.
    Yamada S; Yoshioka R; Shibatani T
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):1922-7. PubMed ID: 9433761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparative resolution of etodolac enantiomers by preferential crystallization method.
    Dung PT; Trung TQ; Kim KH
    Arch Pharm Res; 2009 Oct; 32(10):1425-31. PubMed ID: 19898806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride.
    Wang X; Wang XJ; Ching CB
    Chirality; 2002 May; 14(4):318-24. PubMed ID: 11968072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the characterization and crystallization of 4-hydroxy-2-pyrrolidone.
    Wang XJ; Wiehler H; Ching CB
    Chirality; 2004 May; 16(4):220-7. PubMed ID: 15034904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Chiral Resolution of Two Racemic Compounds by Preferential Cocrystallization*.
    Zhou F; Shemchuk O; Charpentier MD; Matheys C; Collard L; Ter Horst JH; Leyssens T
    Angew Chem Int Ed Engl; 2021 Sep; 60(37):20264-20268. PubMed ID: 34233036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anion effect on the binary and ternary phase diagrams of chiral medetomidine salts and conglomerate crystal formation.
    Choobdari E; Fakhraian H; Peyrovi MH
    Chirality; 2014 Mar; 26(3):183-8. PubMed ID: 24574075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and chromatographic properties of 1,3-thiazane-2-carboxylic acid (beta-homothiaproline).
    Foppoli C; Cini C; Blarzino C; De Marco C
    Ital J Biochem; 1980; 29(4):251-9. PubMed ID: 7216718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of preferential crystallization to resolve racemic compounds in a hybrid process.
    Lorenz H; Polenske D; Seidel-Morgenstern A
    Chirality; 2006 Nov; 18(10):828-40. PubMed ID: 16917833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for conglomerate in set of [7]helquat salts: multigram resolution of helicene-viologen hybrid by preferential crystallization.
    Vávra J; Severa L; Císařová I; Klepetářová B; Šaman D; Koval D; Kašička V; Teplý F
    J Org Chem; 2013 Feb; 78(4):1329-42. PubMed ID: 22957746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.